Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are being made, and clinical research has resumed in many areas, according to the latest Evaluate Vantage report.
Compared to the same period in 2020, the medtech industry has witnessed a reversal of fortunes. Those producing Covid-19 tests and treatment technologies have lost headway, while demand for devices used in non-urgent procedures, in the orthopaedic and cardiovascular fields for instance, is surging.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze